These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29023678)

  • 1. Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence.
    Rostami-Hodjegan A
    Clin Pharmacol Ther; 2018 Feb; 103(2):224-232. PubMed ID: 29023678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Centered Reverse Translation.
    Wagner JA
    Clin Pharmacol Ther; 2018 Feb; 103(2):168-170. PubMed ID: 29210055
    [No Abstract]   [Full Text] [Related]  

  • 3. Model-Informed Reverse and Forward Translation of Safety Risks in Drug Development.
    Mettetal JT
    Clin Pharmacol Ther; 2018 Feb; 103(2):199-201. PubMed ID: 29194584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedside to Bench: Integrating Quantitative Clinical Pharmacology and Reverse Translation to Optimize Drug Development.
    Gibbs JP; Menon R; Kasichayanula S
    Clin Pharmacol Ther; 2018 Feb; 103(2):196-198. PubMed ID: 29105747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How Well Are We Applying Quantitative Methods to Reverse Translation to Inform Early Clinical Development?
    Heatherington AC; Kasichayanula S; Venkatakrishnan K
    Clin Pharmacol Ther; 2018 Feb; 103(2):174-176. PubMed ID: 29274086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse Translation for Assessment of Confidence in Animal Models of Multiple Sclerosis for Drug Discovery.
    't Hart BA; Laman JD; Kap YS
    Clin Pharmacol Ther; 2018 Feb; 103(2):262-270. PubMed ID: 28748631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reverse Translation: The Art of Cyclical Learning.
    Kasichayanula S; Venkatakrishnan K
    Clin Pharmacol Ther; 2018 Feb; 103(2):152-159. PubMed ID: 29313963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy From Strange Sources.
    Lesko LJ
    Clin Pharmacol Ther; 2018 Feb; 103(2):253-261. PubMed ID: 29052220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse and Forward Translational Neuropharmacology in Psychiatric Drug Discovery.
    Shaffer CL
    Clin Pharmacol Ther; 2018 Feb; 103(2):193-195. PubMed ID: 29076553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.
    Brackman DJ; Giacomini KM
    Clin Pharmacol Ther; 2018 Feb; 103(2):233-242. PubMed ID: 29023674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality.
    Miksad RA; Abernethy AP
    Clin Pharmacol Ther; 2018 Feb; 103(2):202-205. PubMed ID: 29214638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing Clinical Prediction Models: Pushing the Needle Towards Precision Pharmacotherapy.
    Dorajoo SR; Chan A
    Clin Pharmacol Ther; 2018 Feb; 103(2):180-183. PubMed ID: 28722146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging Humanized Animal Models to Understand Human Drug Disposition: Opportunities, Challenges, and Future Directions.
    Choo EF; Salphati L
    Clin Pharmacol Ther; 2018 Feb; 103(2):188-192. PubMed ID: 29193027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Next Generation of Drug Safety Science: Coupling Detection, Corroboration, and Validation to Discover Novel Drug Effects and Drug-Drug Interactions.
    Tatonetti NP
    Clin Pharmacol Ther; 2018 Feb; 103(2):177-179. PubMed ID: 29313964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational High-Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models.
    Chiang CW; Zhang P; Wang X; Wang L; Zhang S; Ning X; Shen L; Quinney SK; Li L
    Clin Pharmacol Ther; 2018 Feb; 103(2):287-295. PubMed ID: 29052226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study.
    Wang L; Ingle J; Weinshilboum R
    Clin Pharmacol Ther; 2018 Feb; 103(2):243-252. PubMed ID: 29052219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.
    Yeo KR; Jamei M; Rostami-Hodjegan A
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):143-57. PubMed ID: 23473592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
    Rostami-Hodjegan A
    Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.
    Mao J; Fan P; Wong S; Wang J; Ismaili MHA; Dean B; Hop CECA; Wright M; Chen Y
    Pharm Res; 2017 Nov; 34(11):2403-2414. PubMed ID: 28815392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational Quantitative Systems Pharmacology in Drug Development: from Current Landscape to Good Practices.
    Bai JPF; Earp JC; Pillai VC
    AAPS J; 2019 Jun; 21(4):72. PubMed ID: 31161268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.